Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Celgene Corp (CELG) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 90,760,888
  • Shares Outstanding, K 775,120
  • Annual Sales, $ 9,256 M
  • Annual Income, $ 1,602 M
  • 36-Month Beta 1.74
  • Price/Sales 8.39
  • Price/Book 16.06

Price Performance

See More
Period Period Low Period High Performance
1-Month
113.15 +1.59%
on 01/17/17
122.39 -6.08%
on 01/09/17
-1.67 (-1.43%)
since 12/16/16
3-Month
96.93 +18.59%
on 10/25/16
127.00 -9.49%
on 11/09/16
+15.31 (+15.37%)
since 10/17/16
52-Week
93.05 +23.54%
on 02/03/16
127.00 -9.49%
on 11/09/16
+11.89 (+11.54%)
since 01/15/16

Most Recent Stories

More News
Medidata Solutions Clinical Cloud Gets Picked by Celgene

Medidata Solutions Inc. (MDSO) recently announced that Celgene Corporation adopted Medidata Clinical Cloud.

Trump Attacks Biotech & Pharma: ETFs Bleed

Trump pledged to initiate a bidding process for drug cost that shed roughly $24.6 billion in 20 minutes from the nine biggest pharmaceutical companies by market cap.

Trump Attacks Biotech & Pharma: ETFs Bleed

Trump pledged to initiate a bidding process for drug cost that shed roughly $24.6 billion in 20 minutes from the nine biggest pharmaceutical companies by market cap.

Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short

Several licensing deals and agreements were announced this week including the $5.2 billion ARIAD (ARIA) acquisition.

Celgene Issues Preliminary 2016 Results, Lifts 2017 View

Celgene (CELG) announced preliminary 2016 results and upped guidance for 2017 at the J.P. Morgan Healthcare Conference.

Celgene Corporation Announces Preliminary 2016 Unaudited Results and 2017 Financial Guidance

--Raising 2017 Guidance for Total Revenue and Diluted EPS

Halozyme (HALO) Up on Positive Phase II Data on PEGPH20

Halozyme (HALO) announced top-line data from the combined analysis from its phase II HALO 202 study on PEGPH20.

Bristol-Myers, J&J Ink Immunotherapy Research Collaboration

Bristol-Myers (BMY) entered into an immunotherapy clinical research collaboration with Johnson & Johnson to evaluate a combination of Opdivo and Darzalex.

Celgene Corporation to Announce Fourth Quarter and Full-Year 2016 Results on January 26, 2017

Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, January 26, 2017 at 9 a.m. ET to discuss fourth quarter and full-year 2016 financial and...

Celgene Corporation to Present at the 35th Annual J.P. Morgan Healthcare Conference

During the 35th Annual J.P. Morgan Healthcare Conference on January 9, 2017 at 10:30 a.m. ET, Celgene Corporation (NASDAQ:CELG) will present a business update on the Company in addition to...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.

See More

Support & Resistance

2nd Resistance Point 118.11
1st Resistance Point 116.53
Last Price 114.95
1st Support Level 113.26
2nd Support Level 111.57

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.